PremiumThe FlyRevance, Crown Laboratories amend merger agreement to increase offer price Revance and Crown Laboratories amend merger agreement increasing share offer Crown Laboratories extends tender offer to acquire Revance Therapeutics PremiumThe FlyUnusually active option classes on open December 12th Revance receives acquisition offer from Crown Laboratories for $3.10 per share Unusually active option classes on open December 10th PremiumThe FlyBiotech Alert: Searches spiking for these stocks today Nvidia trades on Dow for first time, Rivian reports downbeat Q3: Morning Buzz Revance Therapeutics Reports Q3 Growth Amid Merger Plans 
